Compugen Names Lead Therapeutic Candidate For CGEN-15029 Immuno-Oncology Program IND filing For COM701 Anticipated in 2017

By: via Benzinga
Compugen Ltd. (NASDAQ: CGEN) announced disclosed COM701 as the lead monoclonal antibody therapeutic candidate for its CGEN-15029 ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.